17 completed, 1 terminated. 18 Phase 2, 3 Phase 3.
By phase and status
Follow grazoprevir: new trials by email Literature Review of grazoprevir trials Research Report on grazoprevir
Trials (filtered) newest first · largest first
All 18 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules - HCV Infection | Phase 2 | Completed | 57 | 2018-01-25 | 2023-05-31 |
A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG - Hepatitis C | Phase 2 | Completed | 129 | 2018-01-19 | 2021-11-18 |
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Completed | 15 | 2016-12-09 | 2025-07-15 |
Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)
Grazoprevir, Elbasvir, Ribavirin - Hepatitis C | Phase 2 | Completed | 101 | 2016-01-05 | 2019-08-13 |
Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir
Grazoprevir/Elbasvir, Sofosbuvir, Ribavirin - Hepatitis C | Phase 2 | Completed | 26 | 2016-01-01 | 2026-06-12 |
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Grazoprevir, Uprifosbuvir, Elbasvir - Hepatitis C | Phase 2 | Completed | 413 | 2015-01-28 | 2019-07-30 |
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
Grazoprevir, Uprifosbuvir, Elbasvir - Hepatitis C | Phase 2 | Completed | 443 | 2015-01-22 | 2019-07-23 |
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
Grazoprevir, Elbasvir, Placebo to Grazoprevir - Hepatitis C | Phase 2 / Phase 3 | Completed | 399 | 2014-08-01 | 2018-09-24 |
Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)
Grazoprevir/Elbasvir FDC, Sofosbuvir - Hepatitis C | Phase 2 | Completed | 143 | 2014-06-13 | 2021-02-05 |
Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)
Grazoprevir (GZR), Elbasvir (EBR), Ribavirin (RBV) - Hepatitis C Virus | Phase 2 | Completed | 79 | 2014-05-23 | 2018-09-24 |
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
Grazoprevir, Elbasvir, MK-5172A - Chronic Hepatitis C | Phase 2 / Phase 3 | Completed | 40 | 2014-05-09 | 2019-06-26 |
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
Grazoprevir, Elbasvir, Placebo to Grazoprevir - Hepatitis C Virus | Phase 2 / Phase 3 | Completed | 237 | 2014-03-17 | 2018-09-24 |
Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
Grazoprevir, Elbasvir, Ribavirin - Hepatitis C | Phase 2 | Completed | 98 | 2013-10-01 | 2021-02-04 |
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Grazoprevir, Elbasvir, Placebo to Elbasvir - Hepatitis C | Phase 2 | Completed | 573 | 2013-02-07 | 2021-02-05 |
A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)
Grazoprevir, Ribavirin - Hepatitis C | Phase 2 | Completed | 26 | 2013-01-18 | 2018-09-24 |
A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)
Grazoprevir, pegylated interferon alfa-2b, Ribavirin - Chronic Hepatitis C (CHC) | Phase 2 | Completed | 87 | 2012-12-07 | 2021-02-04 |
Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
Grazoprevir, Placebo to Grazoprevir, Peginterferon alfa-2b (Peg-IFN) - Hepatitis C, Chronic | Phase 2 | Terminated | 5 | 2011-11-28 | 2024-05-22 |
Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)
Grazoprevir, Boceprevir, Placebo for Grazoprevir - Hepatitis C, Chronic | Phase 2 | Completed | 368 | 2011-06-27 | 2024-05-22 |
Conditions studied
Hepatitis C (14) · Hepatitis C, Chronic (4) · Carcinoma, Hepatocellular (1) · Substance-Related Disorders (1)
Sponsors
Merck Sharp & Dohme LLC (15) · ANRS, Emerging Infectious Diseases (1) · M.D. Anderson Cancer Center (1) · University of Dundee (1)
Countries
United States (2) · France (1) · Germany (1) · Poland (1) · Sweden (1) · United Kingdom (1)
Top investigators
Ahmed O Kaseb, MD (1) · John Dillon, MD (1)
Results publications
PMID 28193518, PMID 28802814, PMID 28802816, PMID 24727022, PMID 25266289, PMID 26353843, PMID 26371152, PMID 26456905, PMID 27291249, PMID 27770561, PMID 27873094, PMID 28470815, PMID 28576451, PMID 29077864, PMID 29152828, PMID 29404492, PMID 29461687, PMID 29473975, PMID 30680407, PMID 30939489, PMID 31399460, PMID 35582875, PMID 36790337, PMID 37096802
NIH funding
2014 (3), 2015 (3), 2017 (1)